Phaseline

Companies › Schrödinger

Schrödinger: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SGR-3515–Phase 1Advanced Solid TumorDec 2026
SGR-1505–Phase 1Mature B-Cell NeoplasmNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06463340SGR-3515Phase 1Advanced Solid TumorOncologyDec 2026
NCT05544019SGR-1505Phase 1Mature B-Cell NeoplasmOncologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.